ArticleIranian journal of basic medical sciences2026
Electroacupuncture preconditioning alleviates myocardial ischemia-reperfusion injury through reducing the inflammatory response mediated by the miR-146a/TRAF6/IRAK4 pathway.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Myocardial ischemia-reperfusion injury (MIRI) lacks effective multi-target interventions. Electroacupuncture (EA) shows cardioprotective potential, but its molecular mechanisms remain incompletely understood. This study aimed to investigate whether EA exerts cardioprotective effects by modulating myocardial miR-146a, a microRNA closely associated with inflammation and cardiovascular diseases. Materials and Methods: A rat model of MIRI was established, and Sprague-Dawley rats were divided into four groups: sham, MIRI, EA treatment, and miR-146a inhibition+EA. Cardiac function, infarct size, myocardial injury, apoptosis, and inflammatory cytokine levels were assessed using echocardiography, TTC staining, CK and LDH assays, TUNEL staining, and ELISA, respectively. The expression and cellular origin of miR-146a were assessed via qRT-PCR, and immunofluorescence. Results: EA treatment significantly improved cardiac function, reduced infarct size, attenuated myocardial injury and apoptosis, and upregulated miR-146a expression in cardiomyocytes. In contrast, inhibition of miR-146a markedly attenuated the protective effects of EA and down-regulated the expression of angiogenic factors bFGF and VEGF, while compromising its anti-inflammatory actions. Furthermore, EA-mediated down-regulation of the inflammatory response was mediated through the miR-146a/TRAF6/IRAK4 pathway. Conclusion: These findings suggest that EA may alleviate MIRI by upregulating myocardial miR-146a expression, providing novel molecular insights into the cardioprotective mechanisms of EA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.